2025年第一期（Vol 14, No 1）

cao1976

Table of Contents
! q! |! {1 C1 C: U7 cArticles @ Virology
1 ^) c0 `0 C( l& V

Current Status and Challenges of Alternative Methods for Potency Testing of Human Rabies Vaccines 8 C  O+ a0 d  q' g; \" p" THan Qiao, Jia Li, Shouchun Cao

PDF 5 o2 P5 r4 j1 P: M 1-12 . L+ Z* h. W, l6 ~, {. `4 X

Getah Virus: From Molecular Evolution to Prevention and Control Strategies 4 c3 Q; l, s3 D4 E& bYaqing Guo, Xinrong Wang, Xinbei Li, Hao Xu, Guoyu Niu

PDF ( q% v3 ?) R5 S3 X: l! r) h 13-20 0 C* C2 ]0 o6 J& Z/ J 7 _6 \( S8 r# [2 j

# c# h# Q+ y" @+ P5 |# {) i2 t& p

cao1976

Current Status and Challenges of Alternative Methods for Potency Testing of Human Rabies Vaccines
5 {+ o. o: N( I2 nHan Qiao, Jia Li, Shouchun Cao

Abstract
% ?1 i" g. [6 U  q, zRabies is a fatal viral disease, and vaccination is an effective means of prevention. Potency testing of rabies vaccines is crucial for ensuring vaccine quality. Currently, the NIH method is widely regarded as the gold standard for rabies vaccine potency testing; however, this method has limitations, including complexity, time consumption, and ethical concerns regarding animal use. In recent years, research in this field has gradually shifted towards alternative technologies aimed at improving testing efficiency, reducing costs, and addressing animal welfare requirements. This article reviews the research progress of various alternative technologies based on vaccine antigen detection and antibody detection, including enzyme-linked immunosorbent assay, time-resolved methods, rapid fluorescent focus inhibition test, and antibody binding test. It systematically analyzes the principles, technical limitations, and feasibility of these methods as alternatives in vaccine quality control, aiming to provide new insights and theoretical foundations for rabies vaccine potency testing to promote further development in this field.

7 b8 l( V9 j7 g' ?: z$ ?
Keywords
3 r, V! y6 c3 t0 M' ^$ hRabies Vaccine, Potency Testing, NIH method, Method Alternatives, Antigen Detection, Antibody Detection
' z" D% V0 T4 a: [1 _; l

9 t3 ~7 T5 u- u. h: AFull Text:[size=0.85em]PDF
% T; d2 R9 N* e# ~5 n+ T+ Q

! @+ l3 k" J# k: DDOI: https://doi.org/10.21092/jav.v14i1.117
! f+ o& z. K1 O( f; Y4 ?

cao1976

Getah Virus: From Molecular Evolution to Prevention and Control Strategies
8 _; I7 i; p( n/ o. J/ k# KYaqing Guo, Xinrong Wang, Xinbei Li, Hao Xu, Guoyu Niu
* Y  ]( }  V  i, B) r
Abstract
, l( R( q0 m# A

Getah virus (GETV) is an arbovirus belonging to the genus Alphavirus within the family Togaviridae. Since its initial isolation in Malaysia in 1955, GETV has expanded from its original confinement in the island regions of the South Pacific to cover a broad geographical range extending up to 60°N latitude. GETV is a single-stranded, positive-sense RNA virus primarily transmitted by mosquitoes. Studies indicate that the spread of GETV across Eurasia has been increasing. The range of infected animal species has expanded from horses and pigs to include cattle, blue foxes, and red pandas, resulting in significant economic losses to the livestock industry. Although there have been no confirmed reports of GETV causing human disease, antibodies against GETV have been detected in the serum of healthy individuals in several countries, suggesting a potential public health risk. This review provides a systematic overview of the epidemiological characteristics, molecular biology, and public health implications of GETV, with an emphasis on its potential threat to both animal and human health. The spatial and temporal distribution patterns, molecular genetic evolution, clinical implications, public health significance, and future research directions of GETV are discussed in detail.

/ I( Q0 l3 X# E- o
0 i" ]* e. `3 _' V5 \Keywords
6 u2 v" c+ n% z' }5 yGetah Virus; Geographic Distribution; Genetic Structure; Diagnosis; Prevention

6 D. ]. s9 V/ X4 V
Full Text:[size=0.85em]PDF
2 b, s0 |& v+ {+ O7 B

DOI: https://doi.org/10.21092/jav.v14i1.100